Literature DB >> 21226632

Revascularization treatment of stable coronary artery disease.

Michael Magro1, Scot Garg, Patrick W Serruys.   

Abstract

INTRODUCTION: Coronary artery disease (CAD) is the leading cause of mortality in developed countries. Angina, myocardial infarction, heart failure and other clinical manifestations of coronary atherosclerosis lead to considerable patient morbidity and constitute an increasingly heavy burden on health systems worldwide. AREAS COVERED: This article reviews the recent major developments in the treatment of CAD, which can be achieved using medical therapy either in isolation or in combination with revascularization, performed via coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI). There is no dispute that optimal medical treatment is the cornerstone of CAD management; however, timely revascularization offers superior symptom control in patients with severe symptoms and may also offer a survival advantage in some patients with diffuse disease and diabetes. Importantly, the advances in PCI technology, especially with the introduction of drug-eluting stents has narrowed the gap between CABG and PCI for the treatment of CAD. EXPERT OPINION: The continuous developments in diagnosis and treatment of CAD call for contemporary trials with detailed analysis to provide evidence that will help in the choice of the best and most cost-effective treatment strategy.

Entities:  

Mesh:

Year:  2011        PMID: 21226632     DOI: 10.1517/14656566.2010.517522

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

1.  Danshensu protects isolated heart against ischemia reperfusion injury through activation of Akt/ERK1/2/Nrf2 signaling.

Authors:  Jiahui Yu; Lingyan Wang; Mary Akinyi; Yuhong Li; Zhenzhen Duan; Yan Zhu; Guanwei Fan
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Ginsenoside Rg3-loaded, reactive oxygen species-responsive polymeric nanoparticles for alleviating myocardial ischemia-reperfusion injury.

Authors:  Lan Li; Yili Wang; Rui Guo; Sheng Li; Jingyu Ni; Shan Gao; Xiumei Gao; Jingyuan Mao; Yan Zhu; Pingli Wu; Hongjun Wang; Deling Kong; Han Zhang; Meifeng Zhu; Guanwei Fan
Journal:  J Control Release       Date:  2019-11-26       Impact factor: 9.776

Review 3.  Mechanisms of load dependency of myocardial ischemia reperfusion injury.

Authors:  Mahmood S Mozaffari; Jun Yao Liu; Worku Abebe; Babak Baban
Journal:  Am J Cardiovasc Dis       Date:  2013-11-01

4.  Angiographic estimation of atherosclerotic disease burden in a coronary artery fed by collaterals: a potential pitfall in decision for revascularization.

Authors:  Grigorios Tsigkas; Panagiota Mylona; Periklis Davlouros; Dimitrios Alexopoulos
Journal:  Vasc Health Risk Manag       Date:  2011-03-22

5.  Danshensu alleviates cardiac ischaemia/reperfusion injury by inhibiting autophagy and apoptosis via activation of mTOR signalling.

Authors:  Guanwei Fan; Jiahui Yu; Patrick Fordjour Asare; Lingyan Wang; Han Zhang; Boli Zhang; Yan Zhu; Xiumei Gao
Journal:  J Cell Mol Med       Date:  2016-07-07       Impact factor: 5.310

6.  Metformin suppresses inflammation and apoptosis of myocardiocytes by inhibiting autophagy in a model of ischemia-reperfusion injury.

Authors:  Kai-Yu Huang; Jia-Qun Que; Ze-Song Hu; Yong-Wei Yu; Ying-Ying Zhou; Lei Wang; Yang-Jing Xue; Kang-Ting Ji; Xin-Min Zhang
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.